As immunotherapy lacks valid and predictive peripheral biomarkers and lymphocytes play a key role in tumor killing in immunotherapy, another aim of the present study was to understand whether germline variants in DDR genes may suggest a new target for poor responders to anti-PD-L1 drugs. This evidence concerns the gene CD274 and neoplasm.